William Blair analyst Andy Hsieh believes shares of ImmunoGen offer an attractive risk/reward at current valuation levels. After surveying 25 key opinion leaders in the field of gynecologic oncology, the analyst says ovarian cancer KOLs hold a favorable view of mirvetuximab soravtansine’s clinical profile. Hsieh reiterates an Outperform rating on ImmunoGen.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.